1. People's Republic of China Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
Cathay Biotech Inc.

Cathay Biotech Inc.

688065.SS
Cathay Biotech Inc.CN flagShanghai Stock Exchange
49.46
CNY
+0.22
- -
35.67BMarket Cap
Cathay Biotech Inc.
688065.SS
(Shanghai Stock Exchange)

Recent

price

49.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
3.77
2.76
4.05
4.19
3.63
5.08
4.82
5.35
Revenue per Share
- -
- -
- -
0.94
0.84
1.02
0.95
0.63
0.84
0.82
0.92
Basic EPS, GAAP
- -
- -
- -
-0.3
-0.46
-1.51
-5.83
-1.72
-0.04
-0.5
-1.07
Free Cash Flow per Basic Share
- -
- -
- -
0.24
0.01
0.58
0.36
0.24
0.24
0.46
0.24
Dividend per Share
- -
- -
- -
2.28
2.97
3.2
4.1
4.56
4.96
4.83
5.12
Book Value per Share
- -
- -
- -
8.68
20.73
23.85
24.49
24.18
24.77
30.11
34.23
Tangible Book Value per Share
- -
- -
- -
508
543
583
582
582
582
684
595
Basic Weighted Avg Shares
929
1,363
1,757
1,916
1,497
2,363
2,441
2,114
2,958
3,295
3,184
Sales/Revenue/Turnover
20.86
31.62
29.19
29.55
33.07
22.65
18.56
12.93
16.46
20.46
17.89
Operating Margin (%)
35
46
73
116
118
169
265
286
321
316
- -
Depreciation Expense
145
333
466
479
458
595
553
367
489
561
550
Net Income, GAAP
26.35
15.29
13.81
13.85
12.18
12.55
11.97
9
13.4
15.97
15.52
Effective Tax Rate (%)
15.66
24.42
26.54
24.99
30.57
25.16
22.66
17.34
16.53
17.02
17.28
Profit Margin (%)
367
101
310
1,666
8,010
10,177
7,051
4,161
4,469
9,725
10,136
Working Capital
- -
- -
- -
80
- -
- -
960
245
613
189
493
LT Debt
1,219
2,197
3,157
4,642
11,484
14,674
15,038
14,773
15,101
21,315
21,075
Total Equity
- -
20.77
15.88
11.84
5.29
3.47
2.52
1.52
2.51
2.91
2.54
Return on Invested Capital (%)
- -
80.91
64.61
43.03
22.13
12.21
7.19
4.52
6.42
7.59
8.07
Return on Capital (%)
- -
89.2
74.78
51.34
33.04
34.22
26.01
14.54
17.65
18.12
18.85
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,284
1,012
62
LT Borrowings
613
623
493
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
583
721
721
Market Capitalization
22,689
29,962
28,045

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
7,387
12,948
12,012
Cash, Cash Equivalents & STI
5,347
10,798
9,823
Accounts Receivable, Net
247
328
348
Inventories
1,181
1,164
1,162
Total Current Liabilities
2,918
2,538
1,876
Payables & Accruals
- -
- -
- -
ST Debt
1,284
1,012
62
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.37%
41.15%
Free Cash Flow
- -
357.61%
1,415.99%
Net Income, GAAP
- -
7.46%
14.68%
Sales/Revenue/Turnover
- -
19.81%
11.4%
Total Cash Common Dividend
- -
1,744.9%
122.34%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
685
760
771
743
2,958
2025
776
895
750
- -
3,295
2026
875
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
- -
- -
- -
0.84
2025
0.23
- -
- -
- -
0.82
2026
0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.24
2025
0.02
- -
- -
- -
0.46
2026
- -
- -
- -
- -
- -
Similar Companies
Tronox Pigmentos do Brasil S.A. (CRPG5.SA)
Redox Limited (RDX.AX)
Luyang Energy-Saving Materials Co., Ltd. (002088.SZ)
Jiangsu Huaxicun Co.,Ltd. (000936.SZ)
Zhejiang Juhua Co., Ltd. (600160.SS)
LyondellBasell Industries N.V. (0EDD.L)
Business
Cathay Biotech Inc. (688065.SS) researches, develops, produces and sells bio-based materials utilizing synthetic biology and bio-manufacturing technology in China and internationally. The company, founded in 2000 and headquartered in Shanghai at Building 5, 1690 Cailun Road, Zhangjiang Hi-Tech Park, focuses on the polyamide industry value chain; its core products include biological long-chain diacids such as sebacic acid (DC10), octadecanedioic acid (DC18) and other dibasic acids (DC11-DC36); bio-based pentamethylene diamine (PDA or DN5); and a series of bio-based polyamides including TERRYL for textile applications and ECOPENT for engineering materials; these serve industries including textiles, pharmaceuticals, perfumes, automobiles, electronic appliances, consumer goods, engineering materials and transportation. Cathay Biotech operates production sites in Jinxiang and Wusu, with R&D centers in Shanghai; it exports products globally under its brands. In recent developments, the company signed a joint venture agreement with South Korea's 3P.COM Co. Ltd. in late 2024 to develop sustainable bio-based composite materials; it partnered with Hefei Municipal Government and China Merchants Innovation Technology in May 2024, followed by a December 2024 announcement for joint investment in Yaoyang Biotechnology (Shanghai) via subsidiaries; earlier in 2023, it entered a major strategic collaboration with China Merchants Group encompassing capital raising, bio-based polyamide procurement targets through 2025, and financing support; it continues expanding with bio-based composite innovations showcased at events like JEC World 2025, SNEC 2024 and CHINAPLAS 2024, including applications in aviation temperature-controlled containers.